Shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) saw unusually-strong trading volume on Monday . Approximately 64,083 shares were traded during mid-day trading, an increase of 146% from the previous session’s volume of 26,033 shares.The stock last traded at $18.12 and had previously closed at $18.40.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. UBS Group increased their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, January 27th. William Blair raised Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.
Get Our Latest Stock Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Trading Down 3.0 %
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- What is diluted earnings per share (Diluted EPS)?
- How to Protect Your Portfolio When Inflation Is Rising
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- 3 REITs to Buy and Hold for the Long Term
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.